Affiliation
Cork Cancer Research Centre, Mercy University Hospital and Leslie C. Quick Jnr., Laboratory, University College Cork, Cork, Ireland.Issue Date
2012-01-31T16:38:08ZMeSH
CTLA-4 Antigen/antagonists & inhibitorsForkhead Transcription Factors/antagonists & inhibitors
Humans
Lymphocyte Depletion
Neoplasms/*immunology/*therapy
T-Lymphocytes, Regulatory/*immunology
Metadata
Show full item recordCitation
Cancer Res. 2011 Nov 15;71(22):6915-20. Epub 2011 Nov 8.Journal
Cancer researchDOI
10.1158/0008-5472.CAN-11-1156PubMed ID
22068034Abstract
Infiltration of tumors by regulatory T cells confers growth and metastatic advantages by inhibiting antitumor immunity and by production of receptor activator of NF-kappaB (RANK) ligand, which may directly stimulate metastatic propagation of RANK-expressing cancer cells. Modulation of regulatory T cells can enhance the efficacy of cancer immunotherapy. Strategies include depletion, interference with function, inhibition of tumoral migration, and exploitation of T-cell plasticity. Problems with these strategies include a lack of specificity, resulting in depletion of antitumor effector T cells or global interruption of regulatory T cells, which may predispose to autoimmune diseases. Emerging technologies, such as RNA interference and tetramer-based targeting, may have the potential to improve selectivity and efficacy.Language
engISSN
1538-7445 (Electronic)0008-5472 (Linking)
ae974a485f413a2113503eed53cd6c53
10.1158/0008-5472.CAN-11-1156
Scopus Count
Collections
Related articles
- Targeting regulatory T cells.
- Authors: Ménétrier-Caux C, Curiel T, Faget J, Manuel M, Caux C, Zou W
- Issue date: 2012 Mar
- CTLA-4 and PD-1 Control of T-Cell Motility and Migration: Implications for Tumor Immunotherapy.
- Authors: Brunner-Weinzierl MC, Rudd CE
- Issue date: 2018
- Regulatory T cell targeting in cancer: Emerging strategies in immunotherapy.
- Authors: Dees S, Ganesan R, Singh S, Grewal IS
- Issue date: 2021 Feb
- Co-administration of RANKL and CTLA4 Antibodies Enhances Lymphocyte-Mediated Antitumor Immunity in Mice.
- Authors: Ahern E, Harjunpää H, Barkauskas D, Allen S, Takeda K, Yagita H, Wyld D, Dougall WC, Teng MWL, Smyth MJ
- Issue date: 2017 Oct 1
- Transient Treg depletion enhances therapeutic anti-cancer vaccination.
- Authors: Fisher SA, Aston WJ, Chee J, Khong A, Cleaver AL, Solin JN, Ma S, Lesterhuis WJ, Dick I, Holt RA, Creaney J, Boon L, Robinson B, Lake RA
- Issue date: 2017 Mar